Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Alzamend Neuro Inc (ALZN)

Alzamend Neuro Inc (ALZN)
0.6900 x 2 0.7071 x 3
Post-market by (Cboe BZX)
0.6900 +0.0100 (+1.47%) 04/22/25 [NASDAQ]
0.6900 x 2 0.7071 x 3
Post-market 0.6900 unch (unch) 16:02 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.6800
Day High
0.7075
Open 0.6800
Previous Close 0.6800 0.6800
Volume 93,436 93,436
Avg Vol 138,537 138,537
Stochastic %K 3.42% 3.42%
Weighted Alpha -91.02 -91.02
5-Day Change -0.0990 (-12.55%) -0.0990 (-12.55%)
52-Week Range 0.6427 - 15.0600 0.6427 - 15.0600
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,490
  • Shares Outstanding, K 6,609
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,950 K
  • EBIT $ -4 M
  • EBITDA $ -4 M
  • 60-Month Beta -0.19
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.06
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.84
  • Most Recent Earnings $-0.19 on 03/10/25
  • Next Earnings Date 03/24/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/25
See More
  • Average Estimate -0.30
  • Number of Estimates 1
  • High Estimate -0.30
  • Low Estimate -0.30
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6667 +3.49%
on 04/17/25
Period Open: 1.0100
1.1300 -38.94%
on 03/25/25
-0.3200 (-31.68%)
since 03/21/25
3-Month
0.6427 +7.36%
on 03/14/25
Period Open: 1.1800
1.2048 -42.73%
on 01/24/25
-0.4900 (-41.53%)
since 01/22/25
52-Week
0.6427 +7.36%
on 03/14/25
Period Open: 6.8500
15.0600 -95.42%
on 08/19/24
-6.1600 (-89.93%)
since 04/22/24

Most Recent Stories

More News
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital

ALZN : 0.6900 (+1.56%)
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

ALZN : 0.6900 (+1.56%)
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

ALZN : 0.6900 (+1.56%)
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

ALZN : 0.6900 (+1.56%)
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

ALZN : 0.6900 (+1.56%)
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Alzamend Neuro, Inc. (NASDAQ:ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease

ALZN : 0.6900 (+1.56%)
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

October 15,

ALZN : 0.6900 (+1.56%)
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference

October 10,

ALZN : 0.6900 (+1.56%)
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease

ALZN : 0.6900 (+1.56%)
New Study Reveals How Classical Music Could Revolutionize Depression Care

In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of patients...

ALZN : 0.6900 (+1.56%)
NBIX : 101.74 (+1.05%)
TAK : 15.33 (+2.68%)
AXSM : 103.82 (+0.80%)
BIIB : 118.89 (+2.06%)

Business Summary

Alzamed Neuro is an early clinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Their mission is to rapidly develop and market safe and effective treatments. Their current pipeline...

See More

Key Turning Points

3rd Resistance Point 0.7325
2nd Resistance Point 0.7200
1st Resistance Point 0.7050
Last Price 0.6900
1st Support Level 0.6775
2nd Support Level 0.6650
3rd Support Level 0.6500

See More

52-Week High 15.0600
Fibonacci 61.8% 9.5526
Fibonacci 50% 7.8514
Fibonacci 38.2% 6.1501
Last Price 0.6900
52-Week Low 0.6427

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro